🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We are so proud of our 2024 Hopkins award winners! Johns Hopkins Rheumatology Phil Seo - ACR Distinguished Service Award Kamini Kuchinad - ACR Distinguished Fellow Award Victoria Ruffing - ARP Award of Merit

In a new study, Johns Hopkins Medicine researchers have developed a T cell antibody therapy that eliminates a type of overactive immune cells in the condition multisystem inflammatory syndrome in children. Elana Shaw shares more on targeting these TRBV11-2+ T cells at #ACR24

.Brit Adler explains why rheumatologists should be familiar with dysautonomia and POTS at #ACR24 youtu.be/HHRc4houomw

Laura Cappelli, Julie J. Paik, and Brit Adler on what they're excited about at #ACR24 youtu.be/bvyKdMNJ4lo

#ACR24 Preview: Experts will untangle the complexities of mixed connective tissue disease in this year's Great Debate. Read more in ACR Convergence Today → acr.tw/48PUeJx

‼️ Andrea Fava discusses urinary biomarkers in lupus nephritis at #ACR24 ‼️ youtu.be/wTeKacnAd0Q

Long-term steroid treatments for autoimmune diseases are hard on the body. Hear Brit Adler moderate this session on how clinicians view the future of steroid therapies and autoimmune care, including personalized doses and tapering steroid use. #ACR24

Autoantibodies against Transcription Factor A Mitochondria TFAM are associated with vascular events in lupus. Felipe Andrade & Eduardo Gomez-Banuelos share how lupus patients with anti-TFAM autoantibodies are at higher risk for unfavorable health outcomes at #ACR24

Congrats to Jin Liu for being awarded the ACR Emerging Investigator Excellence Award for her work on 9G4-targeted CAR/cTCR-T cells for the treatment of lupus. #ACR24 Johns Hopkins Rheumatology #ProundMentorMoment

Congrats to Steph Glavaris for being awarded the ACR Emerging Investigator Excellence Award for her work on T cell-engaging antibodies to deeply deplete TRBV9+, autoreactive T cells in ankylosing spondylitis and celiac disease. #ACR24 Johns Hopkins Rheumatology Chris Marston #ProundMentorMoment

While at it, if you are interested in learning more about off-the-shelf precision immunotherapies for the treatment of lupus, please join our talk on 9G4xCD3 T cell-engaging antibodies during the SLE - Cellular Therapy Session at 3 PM. #ACR24 Johns Hopkins Medicine Johns Hopkins Rheumatology

Clifton Bingham, Director of Arthritis Center Johns Hopkins Medicine, and Ana-Maria Orbai, Director of the PsA Program share their latest research on rheumatoid and psoriatic arthritis using PROs to evaluate symptoms and treatment success. #ACR24 youtu.be/EEVQ4ofcGu4

CAR-T immunotherapies show promise for treating lupus, but still have safety concerns. Using precision T cell-engaging BsAbs therapy, Max Konig discusses how this new treatment can safely target and eliminate B cells associated with lupus. #ACR24

Targeting autoreactive B-cells in lupus is a successful treatment, but can cause immunosuppression. Jin Liu’s study details a new T-cell therapy that can selectively eliminate certain B cells in patients with lupus, while avoiding complete immunosuppression. #ACR24

A team of Hopkins Rheumatology scientists have created a precision immunotherapy targeting certain T cells, known as TRBV9+ cells. The study, presented by Stephanie Glavaris at #ACR24, says this therapy may help treat spondylarthritis and celiac disease.

Always such a fun time catching up with Johns Hopkins Rheumatology peeps at the Hopkins reunion at #ACR24! LisaChristopherStine never fails to plan an amazing event! #pingpong #hopkins family

Laura Cappelli’s latest research on inflammatory arthritis has uncovered biomarkers associated with the condition, identifying them as possible treatment targets and investigating how they contribute to severity of the disease. #ACR24

Michelle Petri will be presenting multiple papers on lupus at #ACR24, including this one on how a lupus patient’s race, sex and prednisone usage are major risk factors for increasing the chance of fractures.

In a session on new therapies for autoimmune diseases, Max Konig discusses his research with CAR-T cell treatment, showing how specific immune cells can be targeted to treat conditions such as lupus without compromising the immune system. #ACR24